A Randomized, Double-Blind Study of the Effect on Sustained Viral Response, and the Safety, of Standard or 360 ug PEGASYS [peginterferon alfa-2a] Induction Dosing in Combination With Standard or Higher Dose Copegus [ribavirin] in Treatment-Naive Chronic Hepatitis C Patients Weighing greater than 85kg With Genotype 1 High Viral Titer Infection.

Trial Profile

A Randomized, Double-Blind Study of the Effect on Sustained Viral Response, and the Safety, of Standard or 360 ug PEGASYS [peginterferon alfa-2a] Induction Dosing in Combination With Standard or Higher Dose Copegus [ribavirin] in Treatment-Naive Chronic Hepatitis C Patients Weighing greater than 85kg With Genotype 1 High Viral Titer Infection.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Mar 2013

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms PROGRESS
  • Most Recent Events

    • 26 May 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
    • 04 May 2010 Results have been presented at Digestive Disease Week (DDW) 2010.
    • 18 Apr 2010 Results presented at the 45th Annual Meeting of the European Association for the Study of the Liver.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top